Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer.

导出 OA

翻译打印收藏纠错

作者： Pere,Puig ^[1] ; Nadina,Erill ^[2] ; Marta,Terricabras ^[2] ; Isaac,Subirana ^[2] ; Judit,González-García ^[2] ; Adrià,Asensi-Puig ^[2] ; Michael J,Donovan ^[3] ; Lourdes,Mengual ^[4] ; M Teresa,Agulló-Ortuño ^[5] ; Mireia,Olivan ^[6] ; Antonio,Alcaraz ^[4] ; José A,López-Martín ^[5] ; Inés,de Torres ^[6] ; José Luis,Rodríguez-Peralto ^[5] ; Alfredo,Rodríguez-Antolín ^[5] ; Juan,Morote ^[6] ; Víctor,González-Rumayor ^[2]

作者单位： R&D Department, Atrys Health, Barcelona, Spain. ppuig@atryshealth.com. ^[1] R&D Department, Atrys Health, Barcelona, Spain. ^[2] Icahn School of Medicine at Mount Sinai, MSSM, New York City, USA. ^[3] Department and Laboratory of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. ^[4] Pathology Department, Urology Department and Laboratory of Translational Oncology, Instituto de Investigación Hospital, 12 de Octubre (i + 12), Madrid, Spain. ^[5] Group of Biomedical Research in Urology, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. ^[6]

关键词 Active β-catenin HLA class1 Prostate cancer Systems pathology Wnt/β-catenin pathway